SCHEMBL6016975

SCHEMBL6016975

COc1ccc(C(=O)Nc2ccc(Cc3nc(Cl)[c]c(N(C)CC(=O)NC4CCCC4)n3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.43
CXCR6 O00574 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
EPHX1 P07099 1/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 2/20 0.40
GAA P10253 2/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ACKR3 P25106 2/20 0.40
ADORA3 P0DMS8 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017031 0.92 GAA (0.42) NPC1RAB9AEPHX1GAASMN1; SMN2
SCHEMBL5961348 0.91 HDAC1 (0.43) NPC1RAB9AEPHX1KMT2AMEN1
SCHEMBL5961338 0.90 TBXA2R (0.40) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL6016947 0.88 KMT2A (0.41) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL5961345 0.88 ACKR3 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL5961320 0.84 EPHX1 (0.41) EPHX2NPC1RAB9AEPHX1KMT2A
SCHEMBL5961317 0.83 EPHX2 (0.41) EPHX2NPC1RAB9AEPHX1KMT2A
SCHEMBL6016971 0.82 HDAC1 (0.44) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL1652441 0.82 PTGDR2 (0.50) EPHX2CXCR6NPC1RAB9AEPHX1
SCHEMBL6016869 0.81 GAA (0.40) EPHX2NPC1RAB9AEPHX1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1471057-A1 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 Bayer HealthCare AG (DE) 2004-10-27 EP claimed
EP-1633726-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 Actimis Pharmaceuticals, Inc., (US) 2006-03-15 EP disclosed
WO-2004096777-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 ACTIMIS PHARMACEUTICALS, INC. (US) 2004-11-11 WO disclosed